trending Market Intelligence /marketintelligence/en/news-insights/trending/gycxgQYPy32Qk5ou9GKweA2 content esgSubNav
In This List

Pfizer receives FDA approval to remove boxed warning on smoking drug

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Pfizer receives FDA approval to remove boxed warning on smoking drug

The U.S. FDA authorized label revisions to Pfizer Inc.'s Chantix.

The pharma giant is no longer required to make boxed warnings regarding serious neuropsychiatric events that lead to anxiety and depression.

Chantix is a prescription medication that helps adults 18 and over to quit smoking. The treatment is considered superior to bupropion or nicotine patches.

The revision may further encourage smokers and healthcare providers to discuss smoking cessation treatment options, Pfizer said in a statement.